The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Neovii Pharmaceuticals Appoints Frédéric Prince As Chief Executive Officer
PRIVATEJan 02, 2026•6 months ago
Position
Chief Executive Officer
Company
Neovii
Frédéric Prince
Rapperswil JonaBiotechnologyHealth Care
Description
Frédéric Prince has been appointed as the new Chief Executive Officer of Neovii Pharmaceuticals AG, succeeding Dr Christian Loss, effective January 1st, 2026. The Board of Directors welcomes Dr Prince, confident in his ability to drive the company's growth.
Company Information
Company
Neovii
Location
Rapperswil Jona, St. Gallen, Switzerland
About
Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.
Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.
Rapperswil JonaBiotechnologyHealth Care